InflaRx N.V. (IFRX) vs Vicore Pharma AB (VCRE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Vicore Pharma AB is the larger company by market cap ($255.5 million vs $238.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IFRX | VCRE |
|---|---|---|
| Share price | $1.62 | $9.07 |
| Market cap | $238.74M | $255.45M |
| 1-day change | +5.90% | +2.83% |
| YTD return | +51.49% | — |
| 1-year return | +4.08% | — |
| 5-year return | -38.06% | — |
| EPS (TTM) | $-0.58 | $-2.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.95 | $17.80 |
| 52-week low | $0.798 | $7.88 |
| Distance from 52-week high | -45.07% | -49.04% |
| Analyst consensus | none | none |
| Avg. price target upside | +374.07% | +265.60% |
| Average volume | 798.72K | 16.22K |
| Shares outstanding | 147.37M | 28.16M |
| Employees | 65 | 46 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About InflaRx N.V.
IFRX stock →InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 65 employees
About Vicore Pharma AB
VCRE stock →Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary hypertension.
Health Care · Biotechnology: Pharmaceutical Preparations · 46 employees
IFRX vs VCRE FAQ
Which is bigger, InflaRx N.V. or Vicore Pharma AB?
Vicore Pharma AB (VCRE) is larger, with a market capitalization of $255.45M compared with $238.74M for InflaRx N.V. (IFRX).
Are InflaRx N.V. and Vicore Pharma AB in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.